Behrouz Golichenari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Behrouz Golichenari has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Rahim Nosrati
Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
5 shared publications Aref Farokhi-Fard
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, 1316943551, Iran
4 shared publicationsAlireza Nezami
Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications- Farzam Vaziri
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
3 shared publications - Javad Behravan
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
3 shared publications - Aristidis Tsatsakis
Center of Toxicology & Science Applications, Medical School, University of Crete, 71003 Heraklion, Greece
2 shared publications
Latest Publications
- 1 December 2019
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 146, 111731
Electroanalysis of isoniazid and rifampicin: Role of nanomaterial electrode modifiers
- 1 December 2019
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 146, 111731
Electroanalysis of isoniazid and rifampicin: Role of nanomaterial electrode modifiers
- 25 September 2019
- Published by Taylor & Francis in Critical Reviews in Biotechnology
- Vol. 39 (8) , 1056-1077
Electrochemical-based biosensors for detection ofMycobacterium tuberculosisand tuberculosis biomarkers
Early detection of tuberculosis (TB) reduces the interval between infection and the beginning of treatment. However, commercially available tests cannot discriminate between BCG-vaccinated healthy persons and patients. Also, they are not suitable to be used for immunocompromised persons. In recent years, biosensors have attracted great attention due to their simple utility, accessibility, and real-time outputs. These sensors are increasingly being considered as pioneering tools for point-of-care diagnostics in communities with a high burden of TB and limited accessibility to reference laboratories. Among other types of biosensors, the electrochemical sensors have the advantages of low-cost operation, fast processing, simultaneous multi-analyte analyzing, operating with turbid samples, comparable sensitivity and readily available miniaturization. Electrochemical biosensors are sub-divided into several categories including: amperometric, impedimetric, potentiometric, and conductometric biosensors. The biorecognition element in electrochemical biosensors is usually based on antibodies (immunosensors), DNAs or PNAs (genosensors), and aptamers (aptasensors). In either case, whether an interaction of the antigen–antibody/aptamer or the hybridization of probe with target mycobacterial DNA is detected, a change in the electrical current occurs that is recorded and displayed as a plot. Therefore, impedimetric-based methods evaluate resistance to electron transfer toward an electrode by a Nyquist plot and amperometric/voltammetric-based methods weigh the electrical current by means of cyclic voltammetry, square wave voltammetry, and differential pulse voltammetry. Electrochemical biosensors provide a promising scope for the new era of diagnostics. As a consequence, they can improve detection of Mycobacterium tuberculosis traces even in attomolar scales.
- 25 September 2019
- Published by Taylor & Francis in Critical Reviews in Biotechnology
- Vol. 39 (8) , 1056-1077
Electrochemical-based biosensors for detection ofMycobacterium tuberculosisand tuberculosis biomarkers
Early detection of tuberculosis (TB) reduces the interval between infection and the beginning of treatment. However, commercially available tests cannot discriminate between BCG-vaccinated healthy persons and patients. Also, they are not suitable to be used for immunocompromised persons. In recent years, biosensors have attracted great attention due to their simple utility, accessibility, and real-time outputs. These sensors are increasingly being considered as pioneering tools for point-of-care diagnostics in communities with a high burden of TB and limited accessibility to reference laboratories. Among other types of biosensors, the electrochemical sensors have the advantages of low-cost operation, fast processing, simultaneous multi-analyte analyzing, operating with turbid samples, comparable sensitivity and readily available miniaturization. Electrochemical biosensors are sub-divided into several categories including: amperometric, impedimetric, potentiometric, and conductometric biosensors. The biorecognition element in electrochemical biosensors is usually based on antibodies (immunosensors), DNAs or PNAs (genosensors), and aptamers (aptasensors). In either case, whether an interaction of the antigen–antibody/aptamer or the hybridization of probe with target mycobacterial DNA is detected, a change in the electrical current occurs that is recorded and displayed as a plot. Therefore, impedimetric-based methods evaluate resistance to electron transfer toward an electrode by a Nyquist plot and amperometric/voltammetric-based methods weigh the electrical current by means of cyclic voltammetry, square wave voltammetry, and differential pulse voltammetry. Electrochemical biosensors provide a promising scope for the new era of diagnostics. As a consequence, they can improve detection of Mycobacterium tuberculosis traces even in attomolar scales.
- 9 January 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (8) , 12569-12580
Shedding light on the EpCAM: An overview
The epithelial cell adhesion molecule (EpCAM) is a Type I transmembrane superficial glycoprotein antigen that is expressed on the surface of basolateral membrane of multiple epithelial cells with some exceptions such as epidermal keratinocytes, hepatocytes, thymic cortical epithelial cells, squamous stratified epithelial cells, and myoepithelial cells that do not express the molecule. The molecule plays a pivotal role in the structural integrity, adhesion of the epithelial tissues and their interaction with the underlying layers. EpCAM prevents claudin‐7 and claudin‐1 molecules from degradation, thereby, decreasing the number of tight junctions and cellular interconnections, and promoting the cells toward carcinogenic transformation. Moreover, the mutations in the EpCAM gene lead to congenital tufting enteropathy, severe intestinal epithelium homeostasis disorders, and Lynch and Lynch syndrome. Overexpression of EpCAM on stem cells of some cancers and the presence of this molecule on circulating tumor cells (CTCs) makes it a promising candidate for cancer diagnosis as well as tracing and isolation of CTCs.
- 9 January 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (8) , 12569-12580
Shedding light on the EpCAM: An overview
The epithelial cell adhesion molecule (EpCAM) is a Type I transmembrane superficial glycoprotein antigen that is expressed on the surface of basolateral membrane of multiple epithelial cells with some exceptions such as epidermal keratinocytes, hepatocytes, thymic cortical epithelial cells, squamous stratified epithelial cells, and myoepithelial cells that do not express the molecule. The molecule plays a pivotal role in the structural integrity, adhesion of the epithelial tissues and their interaction with the underlying layers. EpCAM prevents claudin‐7 and claudin‐1 molecules from degradation, thereby, decreasing the number of tight junctions and cellular interconnections, and promoting the cells toward carcinogenic transformation. Moreover, the mutations in the EpCAM gene lead to congenital tufting enteropathy, severe intestinal epithelium homeostasis disorders, and Lynch and Lynch syndrome. Overexpression of EpCAM on stem cells of some cancers and the presence of this molecule on circulating tumor cells (CTCs) makes it a promising candidate for cancer diagnosis as well as tracing and isolation of CTCs.
- 1 October 2018
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 117, 319-331
Nano-biosensing approaches on tuberculosis: Defy of aptamers
- 1 October 2018
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 117, 319-331
Nano-biosensing approaches on tuberculosis: Defy of aptamers
- 1 August 2018
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 113, 124-135
Label-free nano-biosensing on the road to tuberculosis detection
- 1 August 2018
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 113, 124-135
Label-free nano-biosensing on the road to tuberculosis detection
- 10 May 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (6) , 718-725
Recombinant Protein Expression in Escherichia coli (E.coli): What We Need to Know
Background: Host, vector, and culture conditions (including cultivation media) are considered among the three main elements contributing to a successful production of recombinant proteins. Accordingly, one of the most common hosts to produce recombinant therapeutic proteins is Escherichia coli. Methodology: A comprehensive literature review was performed to identify important factors affecting production of recombinant proteins in Escherichia coli. Results: Escherichia coli is taken into account as the easiest, quickest, and cheapest host with a fully known genome. Thus, numerous modifications have been carried out on Escherichia coli to optimize it as a good candidate for protein expression and; as a result, several engineered strains of Escherichia coli have been designed. In general; host strain, vector, and cultivation parameters are recognized as crucial ones determining success of recombinant protein expression in Escherichia coli. In this review, the role of host, vector, and culture conditions along with current pros and cons of different types of these factors leading to success of recombinant protein expression in Escherichia coli were discussed. Conclusion: Successful protein expression in Escherichia coli necessitates a broad knowledge about physicochemical properties of recombinant proteins, selection among common strains of Escherichia coli and vectors, as well as factors related to media including time, temperature, and inducer.
- 10 May 2018
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 24 (6) , 718-725
Recombinant Protein Expression in Escherichia coli (E.coli): What We Need to Know
Background: Host, vector, and culture conditions (including cultivation media) are considered among the three main elements contributing to a successful production of recombinant proteins. Accordingly, one of the most common hosts to produce recombinant therapeutic proteins is Escherichia coli. Methodology: A comprehensive literature review was performed to identify important factors affecting production of recombinant proteins in Escherichia coli. Results: Escherichia coli is taken into account as the easiest, quickest, and cheapest host with a fully known genome. Thus, numerous modifications have been carried out on Escherichia coli to optimize it as a good candidate for protein expression and; as a result, several engineered strains of Escherichia coli have been designed. In general; host strain, vector, and cultivation parameters are recognized as crucial ones determining success of recombinant protein expression in Escherichia coli. In this review, the role of host, vector, and culture conditions along with current pros and cons of different types of these factors leading to success of recombinant protein expression in Escherichia coli were discussed. Conclusion: Successful protein expression in Escherichia coli necessitates a broad knowledge about physicochemical properties of recombinant proteins, selection among common strains of Escherichia coli and vectors, as well as factors related to media including time, temperature, and inducer.
- 1 December 2017
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 97, 428-444
Helicobacter pylori point-of-care diagnosis: Nano-scale biosensors and microfluidic systems
- 1 December 2017
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 97, 428-444
Helicobacter pylori point-of-care diagnosis: Nano-scale biosensors and microfluidic systems
- 1 September 2017
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 94, 95-105
Nanomaterial-based aptasensors and bioaffinity sensors for quantitative detection of 17β-estradiol
- 1 September 2017
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 94, 95-105
Nanomaterial-based aptasensors and bioaffinity sensors for quantitative detection of 17β-estradiol